Ocumension Acquires Two Novartis Products in $35 Million Agreement

Ocumension Therapeutics of Shanghai acquired China rights (including manufacturing) for two approved ophthalmic drugs from Novartis in a $35 million deal. The drugs, Emadine® and Betopic® S, target conjunctivitis and intraocular internal pressure respectively. Ocumension's ophthalmic drug portfolio now includes 20 products, with four already commercialized and five in Phase III clinical trials worldwide. In 2020, Ocumension completed a $184 million IPO in Hong Kong, and it began building a manufacturing facility in Suzhou earlier this year. More details.... Stock Symbols: (HK: 1477) (NYSE: NVS) Share this with colleagues: // //